Cancer cells undergoing epigenetic transition show short-term resistance and are transformed into cells with medium-term resistance by drug treatment

Abstract

To elucidate the epigenetic mechanisms of drug resistance, epigenetically reprogrammed H460 cancer cells (R-H460) were established by the transient introduction of reprogramming factors. Then, the R-H460 cells were induced to differentiate by the withdrawal of stem cell media for various durations, which resulted in differentiated R-H460 cells (dR-H460). Notably, dR-H460 cells differentiated for 13 days (13dR-H460 cells) formed a significantly greater number of colonies showing drug resistance to both cisplatin and paclitaxel, whereas the dR-H460 cells differentiated for 40 days (40dR-H460 cells) lost drug resistance; this suggests that 13dR-cancer cells present short-term resistance (less than a month). Similarly, increased drug resistance to both cisplatin and paclitaxel was observed in another R-cancer cell model prepared from N87 cells. The resistant phenotype of the cisplatin-resistant (CR) colonies obtained through cisplatin treatment was maintained for 2–3 months after drug treatment, suggesting that drug treatment transforms cells with short-term resistance into cells with medium-term resistance. In single-cell analyses, heterogeneity was not found to increase in 13dR-H460 cells, suggesting that cancer cells with short-term resistance, rather than heterogeneous cells, may confer epigenetically driven drug resistance in our reprogrammed cancer model. The epigenetically driven short-term and medium-term drug resistance mechanisms could provide new cancer-fighting strategies involving the control of cancer cells during epigenetic transition.

Cholesterol Synthesis Is Important for Breast Cancer Cell Tumor Sphere Formation and Invasion

“…Total RNA was extracted with TRIzol (#15596026, Invitrogen) and RNA sequencing was performed by the Macrogen (Seoul, Korea) according to the method described previously [ 23 ]. Briefly, total RNA concentration was calculated by Quant-IT RiboGreen (Invitrogen, #R11490).…”

“…A heatmap of DEGs was created using a MultiExperiment Viewer (The Institute of Genomic Research, Rockville, MD, USA). DEGs were subjected to core analysis using Ingenuity Pathway Analysis (IPA) software (Qiagen, Hilden, Germany), as described previously [ 23 , 24 ].…”

Crystal Structure of the Kinase Domain of MerTK in Complex with AZD7762 Provides Clues for Structure-Based Drug Development

“…Statistical analyses were performed as described previously [ 50 ]. P values were calculated using GraphPad version 7.0d (GraphPad Software Inc., Cary, NC, USA), and those less than 0.05 were considered significant.…”

Omics and Computational Modeling Approaches for the Effective Treatment of Drug-Resistant Cancer Cells

“…Multiple omics data are often generated to examine various biological aspects of drug-resistant cancer cells (Figure 1). Target genotypes and phenotypes examined using omics data (Table 1) include: cancer-associated mutations (Niehr et al, 2018;Marczyk et al, 2020;Sinkala et al, 2021); changes in the expression level of specific genes (Niehr et al, 2018;Nava et al, 2019;Kagohara et al, 2020;Marczyk et al, 2020;Poojan et al, 2020;Sinkala et al, 2021); changes in chromosome structure (Kagohara et al, 2020;Marczyk et al, 2020;Aissa et al, 2021); epigenetic alterations (e.g., methylation or acetylation states of histone • Methylome (reduced representation bisulfite sequencing)…”

“…• ceRNA network for correlation between lncRNA and mRNA levels using RNA-seq data proteins) (Nava et al, 2019;Kagohara et al, 2020;Marczyk et al, 2020;Poojan et al, 2020;Sinkala et al, 2021); and the presence of heterogeneity of a cell population (Niehr et al, 2018), often increasingly examined at a single-cell resolution (Kagohara et al, 2020;Aissa et al, 2021). In a recent study for cell line heterogeneity, for example, application of single-cell DNA and RNA sequencing (RNA-seq) to 20 triple-negative breast cancer (TNBC) patients revealed that rare pre-existing clones having genotypes associated with chemoresistance were adaptively selected in response to neoadjuvant chemotherapy, which subsequently led to acquired transcriptional reprogramming (Kim et al, 2018).…”